Skip to content
Menu

Nektar Therapeutics NKTR

Full chart Compare
Set alert

Price alert · NKTR

All alert types
30.35 USD -2.20 (-6.75%)

As ofNov 20, 2026, 3:40 PM EST

30.17 Day range 31.47
30.17 52-week range 109.00
YTD
-28.23%
1 year
-44.94%

5D -3.11 (-8.29%)

3638ThuFriMonTueWed34.42
Market cap
1.04B
Revenue (ttm)
52.19M
EPS (ttm)
-22.47
Shares out
34.21M
Forward P/E
-3.28
YTD return
-28.23%
1-year return
-44.94%
50-day average
46.15
200-day average
65.01
Enterprise value
691.98M
Volume
801.43K
Avg volume
1.11M
Open
31.31
Previous close
32.54
Day's range
30.17 – 31.47
52-week range
30.17 – 109.00
Beta
1.42
Analysts
Buy
Price target
131.92 (+334.7%)
Earnings date
Mar 11, 2027

Key statistics

PEG ratio
0.31
Price / sales
21.33
Price / book
1.31
Revenue growth
-20.40%
Free cash flow
-152.10M
Total cash
614.36M
Total debt
128.67M
Return on equity
-37.92%
Short % of float
21.79%

Fundamental scorecard

5 of 25 checks passed on NKTR’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NKTR Revenue — quarterly 9.39M
NKTR Net income — quarterly -55.65M
NKTR EPS — quarterly -1.63

Earnings

NKTR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 11, 2027Dec 30, 2026-2.51———
Nov 12, 2026Sep 30, 2026-2.07-1.63+0.44+21.26%
Aug 13, 2026Jun 30, 2026-1.97-1.23+0.74+37.56%
May 7, 2026Mar 31, 2026-1.58-1.82-0.24-15.02%
Mar 12, 2026Dec 31, 2025-2.47-1.78+0.69+28.05%
Nov 6, 2025Sep 30, 2025-2.85-1.85+1.00+35.09%

Upgrades / downgrades

NKTR analyst upgrades and downgrades
DateFirmActionFromTo
Nov 16, 2026Canaccord GenuitymainBuyBuy
Oct 12, 2026UBSinit—Neutral
Oct 12, 2026Leerink Partnersinit—Outperform
Oct 9, 2026BTIGreitBuyBuy
Oct 9, 2026Raymond Jamesinit—Market Perform
Oct 2, 2026HC Wainwright & Co.reitBuyBuy

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
nektar.com

News

Your note

Sign in to keep a note on NKTR — it syncs with the Stock Master app.

Insider holders

NKTR insider holders
InsiderRelationLatest transactionDateShares held
ROBIN HOWARD WChief Executive OfficerSaleAug 17, 202654,655
WILSON MARK ANDREWOfficerSaleNov 24, 202521,585
ZALEVSKY JONATHANOfficerSaleAug 17, 20269,570

Institution ownership

NKTR institution ownership
Holder% heldSharesValueReported
FMR, LLC14.97%5,121,441166.65MSep 29, 2026
Two Seas Capital Lp9.78%3,345,978108.88MSep 29, 2026
Blackrock Inc.8.39%2,871,46393.44MSep 29, 2026
BVF Inc.6.24%2,134,00769.44MSep 29, 2026
State Street Corporation5.18%1,772,30257.67MSep 29, 2026
Vanguard Capital Management LLC4.39%1,501,60848.86MSep 29, 2026

Fund ownership

NKTR fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund5.41%1,850,47860.21MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.14%1,075,10834.98MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.85%975,22431.73MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.61%892,63729.05MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund1.46%500,35116.28MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund1.24%424,55413.81MSep 29, 2026